|By PR Newswire||
|August 21, 2014 03:15 PM EDT||
NEW YORK, Aug. 21, 2014 /PRNewswire/ -- Bruckner Oncology has initiated an FDA approved Phase II-III clinical trial which adds Vitamin C to chemotherapy "core" regimens (GFLIO and GFLIO-D) for patients with locally advanced and metastatic pancreatic cancer (APC).
Vitamin C was selected for study because there has never been a formal clinical trial of this frequently used, off label vitamin which has long been credited with improving safety and quality of life during chemotherapy. Also, many investigators found Vitamin C improved the effectiveness of specific chemotherapy for specific (not all) tumors under laboratory conditions. A successful test could benefit the nearly 50% of patients with APC and other cancers who now go untreated or undertreated because of safety and efficacy concerns.
SAFETY: The trial will attempt to reproduce the practice's pilot trial in which Vitamin C and the concurrent cores produced a less than one percent rate of clinically significant adverse events. The pilot group had many high risk patients. During Vitamin C co-treatment patients with preexisting symptoms and adverse events safely tolerated treatment and many improved. Standard treatments produce 10%-40% rates of clinically significant severe adverse events, in trials limited to ideal low risk patients.
SURVIVAL: The trial's secondary objective is to reproduce ten years of APC development experience with the cores. Median survival for prior patients with advanced pancreatic cancer including high risk patients, was 16 - 24 months (ASCO 2008, 2012, and 2013), high risk patients, often untreated elsewhere, are eligible for safe treatment with cores including the elderly, the prior treated and those with a poor 2-3 performance status (ASCO 2008). Current standard regimens in trials limited to ideal low risk patients produce MSTs of less than 12 months.
The core regimens were selected as the control because past experience suggests they may provide one of the safest treatment strategies for important anti-cancer drug classes. There are potential lessons applicable to other cancers because the cores also appear to improve the performance of these drugs for other gastrointestinal, ovarian and uterine cancers (ASCO 2006, 2012, AACR 2014).
The core by its novel design attempts to either double or triple the chances to achieve favorable anti-cancer drug interactions, reverse drug resistance and chances for Vitamin C to impact anti-tumor efficacy compared to standard regimens.
The novel trial design allows every patient the early use of Vitamin C and to continue Vitamin C without interruption when there is evidence of benefit.
The investigators caution that this information should not be taken as a general recommendation for use of Vitamin C. Management of Vitamin C requires special monitoring and maintenance of dosage. Vitamin C may not be suitable for combination with some (other) drugs, nor be an effective protectant for standard regimens which produce high rates of severe adverse events. The trial is supported by a grant from The Marcus Foundation.
Contact: [email protected]
Howard W. Bruckner MD, Medical Director
MZB Foundation for Cancer Research, Medical Director
SOURCE Bruckner Oncology
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Su...
Nov. 26, 2015 09:45 AM EST Reads: 350
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Nov. 26, 2015 09:30 AM EST Reads: 362
Nov. 26, 2015 09:00 AM EST Reads: 471
Nov. 26, 2015 08:45 AM EST Reads: 260
Nov. 26, 2015 08:30 AM EST Reads: 185
Nov. 26, 2015 06:45 AM EST Reads: 391
Nov. 26, 2015 06:15 AM EST Reads: 299
Nov. 26, 2015 06:00 AM EST Reads: 350
Nov. 26, 2015 03:45 AM EST Reads: 691
Nov. 26, 2015 03:00 AM EST Reads: 303
Nov. 26, 2015 02:00 AM EST Reads: 188
Nov. 26, 2015 01:30 AM EST Reads: 432
Nov. 26, 2015 01:00 AM EST Reads: 435
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, San...
Nov. 26, 2015 12:00 AM EST Reads: 526
Nov. 26, 2015 12:00 AM EST Reads: 486